A Cost-Effectiveness Analysis of Combination Antiplatelet Therapy for High-Risk Acute Coronary Syndromes: Clopidogrel plus Aspirin versus Aspirin Alone

Schleinitz, Mark D.; Heidenreich, Paul A.

doi:10.7326/0003-4819-142-4-200502150-00007

Cited by 85 publications

(35 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Resource Considerations-Six studies 33,[49][50][51][52][53] examined the cost-effectiveness of combined antiplatelet therapy with clopidogrel plus aspirin vs aspirin alone in patients after a recent ACS. These studies are consistent in demonstrating the cost-effectiveness of combined antiplatelet therapy with clopidogrel plus aspirin compared with aspirin alone after ACS.…”

Section: Aspirin and Clopidogrel Vs Aspirinmentioning

confidence: 99%

Primary and Secondary Prevention of Cardiovascular Disease

Vandvik

Lincoff

Gore

et al. 2012

Chest

415

118

View full text Add to dashboard Cite

Section: Aspirin and Clopidogrel Vs Aspirinmentioning

confidence: 99%

Primary and Secondary Prevention of Cardiovascular Disease

Vandvik

Lincoff

Gore

et al. 2012

Chest

415

118

View full text Add to dashboard Cite

“…After cessation of clopidogrel, platelet function is ~50% of normal at 3 days and back to normal after 7 days. 17 Integrin αIIbβ3 (glycoprotein IIb/IIIa) antagonists are potent inhibitors of platelet function. Three antagonists are currently approved for use in the United States.…”

Section: Medicationsmentioning

confidence: 99%

Acquired Disorders of Platelet Function

Hassan

Kroll

2005

Hematology

View full text Add to dashboard Cite

A qualitative abnormality of platelet function should be considered in patients with mucocutaneous bleeding in the absence of thrombocytopenia or von Willebrand disease. Antiplatelet drugs are the most common cause of acquired platelet disorders leading to bleeding. Uremia, hepatic cirrhosis, myeloma and related disorders, polycythemia vera, essential thrombocythemia, and cardiopulmonary bypass have long been recognized as clinical situations in which platelet dysfunction may contribute to bleeding. When an acquired platelet disorder is suspected, it is useful to examine platelet function by measuring the bleeding time, examining platelet-dependent closure time in a platelet function analyzer and performing platelet aggregometry. When a specific acquired platelet disorder is diagnosed, many treatment options are available including controlling the underlying disease, giving platelet transfusions and administering a hemostatic drug.

show abstract

“…Previous studies (25,26,32,33) using CVD models have also estimated the reduction in CV event risk with combination therapy in cohorts of high-risk patients in the United States and the developing countries. The strength of the present study for Canadian decision makers is that it used Canadian epidemiological and practice pattern data.…”

Section: Discussionmentioning

confidence: 99%